1. Home
  2. MCD vs NVO Comparison

MCD vs NVO Comparison

Compare MCD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MCD

McDonald's Corporation

HOLD

Current Price

$306.65

Market Cap

220.6B

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$40.81

Market Cap

166.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCD
NVO
Founded
1940
1923
Country
United States
Denmark
Employees
N/A
69500
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
220.6B
166.1B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
MCD
NVO
Price
$306.65
$40.81
Analyst Decision
Buy
Hold
Analyst Count
28
11
Target Price
$342.21
$51.00
AVG Volume (30 Days)
2.8M
13.8M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
2.45%
3.27%
EPS Growth
4.92
N/A
EPS
11.95
N/A
Revenue
$26,885,000,000.00
N/A
Revenue This Year
$7.98
N/A
Revenue Next Year
$5.79
$3.88
P/E Ratio
$25.34
$13.60
Revenue Growth
3.72
N/A
52 Week Low
$283.47
$35.12
52 Week High
$341.75
$81.44

Technical Indicators

Market Signals
Indicator
MCD
NVO
Relative Strength Index (RSI) 42.31 62.04
Support Level $301.21 $35.49
Resistance Level $311.51 $50.30
Average True Range (ATR) 4.53 1.00
MACD 0.13 0.76
Stochastic Oscillator 45.39 98.70

Price Performance

Historical Comparison
MCD
NVO

About MCD McDonald's Corporation

McDonald's is the world's largest restaurant brand, with nearly $139 billion in systemwide sales across more than 45,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 62%), with the remainder stemming from company-operated restaurants across three segments: the United States (39% of systemwide sales), international operated markets (35%), and international developmental/licensed markets (26%).

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: